The Beijing Drug Administration co-hosted a symposium in Zhongguancun Life Science Park with Zhongguancun Development Group recently.

The Drug Supervision and Innovation Service Symposium provided policy advice and technical guidance for pharmaceutical enterprises and answered questions for enterprises in connection with drug registration, quality certification, drug innovation encouragement policies and medical device clinical trials.

More than 160 people from 83 pharmaceutical enterprises in Zhongguancun Life Science Park met and exchanged ideas at the symposium. Other participants included representatives from drug, medical device registration, drug examination and approval, and technical audit sectors. Personnel from the new drug approval and technical evaluation department and the State Food and Drug Administration also took part in the event.

The forum promoted the research and development of new drugs and the transformation of scientific achievements. It is also sought to boost large-scale production of major innovative pharmaceutical products in Beijing.

Edited by Chen Zhilin and Michael Thai